Multi-Tracer Positron Emission Tomography in Patients With Solid Tumors

Status Terminated

Clinical Trial Summary

This clinical trial studies multi-tracer positron emission tomography in patients with solid tumors. Diagnostic procedures, such as multi-tracer positron emission tomography, may help measure a patient's response to treatment.

Clinical Trial Description

PRIMARY OBJECTIVES: I. Provide a reliable and validated cadre of positron emission tomography (PET) imaging derived biomarkers that yield a better understanding of: 1) early clinical benefit from various therapeutic agents in investigational and recently approved therapies; 2) efficacy during novel therapeutics in investigational therapeutics and recently approved therapeutics at Huntsman Cancer Institute (HCI); and 3) possible predict prognosis or other long-term outcomes. II. Reveal a more detailed understanding of: (1) the in vivo biologic mechanisms of various therapeutic drugs in investigational therapies and recently approved therapies at HCI (2) information on why particular functional imaging profiles are seen in treated patients. III. Reveal a more detailed understanding of how the combination of molecular imaging derived biomarkers will be potentially useful to physicians for decision making and for explanation of efficacy or outcomes for patients with cancer. IV. Implement and evaluate a new imaging technology for multi-tracer PET imaging of these tracers. OUTLINE: Patients undergo PET scans with fludeoxyglucose (FDG) F 18 (18FDG), fluorine F 18 fluorothymidine (FLT), and water (H2O) O-15 (15O) tracers at baseline and within 7 days of completion of 1 or 2 (if the course is less than 3 weeks) therapeutic agent courses. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01243333
Study type	Interventional
Source	University of Utah
Contact
Status	Terminated
Phase	N/A
Start date	February 2, 2011
Completion date	April 8, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Active, not recruiting	`NCT02243592` - Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Completed	`NCT03445572` - Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer	N/A
Active, not recruiting	`NCT02860039` - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant	Phase 2
Completed	`NCT01946217` - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials	N/A
Completed	`NCT01635413` - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)	N/A
Completed	`NCT00026169` - Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure	Phase 1
Recruiting	`NCT04534075` - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial	Phase 3
Active, not recruiting	`NCT01806129` - Reproductive Health Program in Patients With Cancer	N/A
Recruiting	`NCT03915717` - Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Recruiting	`NCT02280161` - Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
Recruiting	`NCT05520281` - Short-term Psychodynamic Psychotherapy in Serious Physical Illness	N/A
Terminated	`NCT00532064` - Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
Completed	`NCT04990882` - FAPI PET/CT Prospective Interobserver Agreement
Completed	`NCT01896778` - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer	N/A
Recruiting	`NCT05770102` - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Phase 2/Phase 3
Recruiting	`NCT06090266` - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Recruiting	`NCT05886764` - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials	N/A
Completed	`NCT01432431` - Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff	N/A
Completed	`NCT01506440` - Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy